ArticleAnnals of Ibadan postgraduate medicine2025
STIFF PERSON SYNDROME-MANAGING A RARE AUTOIMMUNE DISORDER IN A LOW RESOURCE SETTING: A CASE REPORT.
Article in Annals of Ibadan postgraduate medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stiff Person Syndrome (SPS) is a rare neurological disorder characterized by muscle stiffness and painful muscle spasms. The symptoms often progress slowly and can cause disability. Auto-antibodies to glutamic acid decarboxylase (anti-GAD) have been reported in up to 80% of the classic type of SPS. Delayed diagnosis may occur especially in low-resource settings if a high index of suspicion is not applied when individuals manifest characteristic symptoms. We report a case of a 63-year-old Nigerian female who presented with progressive onset low back pain, lower body rigidity and painful muscle spasm with subsequent loss of ambulation and development of depression. Serologic tests detected high-titer anti-GAD, confirming the diagnosis of SPS. Due to limited availability and the financial implications of out-of-pocket treatment, escalation therapy to immunebased therapy for this neurological disorder was hindered in our case.
Identifiers
40852673PMC12337961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.